Dr. Pinter-Brown Discusses Treatment Decisions for CTCL

Video

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma.

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma (CTCL). At the 17th International Congress on Hematologic Malignancies, Pinter-Brown spoke about the factors that weigh into a physician's decision concerning the treatment of CTCL.

A physician needs to understand which CTCL is being treated. The stage of the disease is also crucial, as it determines whether the disease needs local or systemic treatment. Other considerations include comorbidities, route of administration, and availability of treatment. A physician must also be aware of how quickly a treatment works and how quickly a patient needs a response.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD